Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Bavarian Nordic raises sales guidance after monkeypox vaccine order

Published by Wanda Rich

Posted on May 25, 2022

Featured image for article about Top Stories

COPENHAGEN (Reuters) -Danish biotechnology company Bavarian Nordic on Wednesday lifted its sales outlook and now expects a smaller operating loss this year after signing a contract with an undisclosed country for the supply of its monkeypox vaccine.

Bavarian shares traded up 16% at 1019 GMT and have risen more than 40% since the company announced a similar vaccine supply deal with an undisclosed country on May 19. The stock is down 28% this year.

“We have rapidly adapted to this unprecedented situation and are working closely with other governments to make vaccines available as fast as possible to mitigate the situation,” CEO Paul Chaplin said in a statement.

The firm is currently in discussions with several other countries about potential supply agreements for its Imvanex monkeypox vaccine, which is branded Jynneos in the United States.

Germany on Tuesday announced it had ordered 40,000 doses of Bavarian’s vaccine, but the firm has not confirmed whether it has entered any deal with Germany.

Bavarian now expects revenue to be between 1.3 and 1.5 billion Danish crowns ($187-$215 million), up from a previous estimate in the range of 1.1 and 1.4 billion.

It also raised its expectations for earnings before interest, tax and amortisation (EBITDA) to a loss of between 1 and 1.2 billion, up from a previous estimate of a loss of 1-1.3 billion.

Global health officials have tracked more than 200 suspected and confirmed cases of the usually mild viral infection in 19 countries since early May.

($1 = 6.9698 Danish crowns)

(Reporting by Nikolaj Skydsgaard, additional reporting by Stine Jacobsen; editing by Jason Neely)